HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
Clinical trials for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) explained in plain language.
Never miss a new study
Get alerted when new HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH) trials appear
Sign up with your email to follow new studies for HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH), keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New drug aims to slash Sky-High cholesterol in rare genetic disease
Disease control OngoingThis phase 3 trial tests VSA003, an RNAi drug that targets a protein called ANGPTL3, in 46 Chinese adolescents and adults with homozygous familial hypercholesterolemia (HoFH), a genetic condition causing extremely high cholesterol. Participants receive either VSA003 or a placebo …
Matched conditions: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
Phase: PHASE3 • Sponsor: Visirna Therapeutics HK Limited • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
Heart attack prevention hope for rare cholesterol disorder
Disease control OngoingThis study tracks 73 adults with homozygous familial hypercholesterolemia (HoFH), a rare genetic disorder causing extremely high cholesterol and early heart disease. Researchers will compare major cardiovascular events (like heart attacks and strokes) during the first three years…
Matched conditions: HOMOZYGOUS FAMILIAL HYPERCHOLESTEROLEMIA (HOFH)
Sponsor: Fondazione SISA (Societa Italiana per lo Studio della Arteriosclerosi) • Aim: Disease control
Last updated Jun 27, 2026 09:06 UTC